The combination of amivantamab and lazertinib shows lower EGFR and MET resistance, offering an advantage over osimertinib alone. Personalized treatment strategies are essential, considering resistance ...

EGFR-positive lung cancer is a type of lung cancer with an epidermal growth factor receptor (EGFR) mutation. In the United States, around 10% to 15% of lung cancers are EGFR-positive. Most of these ...

Panelist discusses how an early analysis of the mechanisms of acquired resistance to first-line treatment with amivantamab plus lazertinib vs osimertinib was presented at the European Society for ...

Despite the PDUFA date being extended by three months for Merus’ zenocutuzumab, Truist Securities analyst Asthika ...

However, the actual molecular mechanism of the anti-inflammatory effect of antithrombin was completely unknown. In a previous study on HRG, Professor Nishibori's research group succeeded in ...

Her primary focus is investigation of the role of the epidermal growth factor receptor family in radiation response. Disclosure: The author declared that she receives clinical trial research ...

Global Phase 1 study of CLN-978 in systemic lupus erythematosus (SLE) cleared to initiate in U.S. and Australia; initial clinical data expected ...

The molecular basis and mechanisms of action of combining classic cytotoxic agents (e.g. platinum-containing drugs, taxanes, etc.) and novel agents (e.g. tirapazamine, EGFR inhibitors and other ...